Edition:
United Kingdom

HTG Molecular Diagnostics Inc (HTGM.OQ)

HTGM.OQ on NASDAQ Stock Exchange Capital Market

3.31USD
20 Jul 2018
Change (% chg)

$0.14 (+4.42%)
Prev Close
$3.17
Open
$3.15
Day's High
$3.33
Day's Low
$3.15
Volume
24,488
Avg. Vol
97,579
52-wk High
$5.82
52-wk Low
$1.59

Chart for

About

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications... (more)

Overall

Beta: --
Market Cap(Mil.): $21.52
Shares Outstanding(Mil.): 11.45
Dividend: --
Yield (%): --

Financials

  HTGM.OQ Industry Sector
P/E (TTM): -- 148.52 32.76
EPS (TTM): -3.00 -- --
ROI: -158.24 9.38 14.61
ROE: -1,928.83 14.71 16.34

BRIEF-HTG Promotes John Lubniewski To President And Chief Operating Officer

* HTG PROMOTES JOHN LUBNIEWSKI TO PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-HTG Molecular Diagnostics Inc Says On March 30, 2018, Co And Qiagen Manchester Limited Entered Second Amendment Of First Statement Of Work

* HTG MOLECULAR DIAGNOSTICS INC - ON MARCH 30, 2018, CO AND QIAGEN MANCHESTER LIMITED ENTERED SECOND AMENDMENT OF FIRST STATEMENT OF WORK - SEC FILING

04 Apr 2018

BRIEF-Htg Molecular Diagnostics Secures Debt Facility With Midcap Financial

* HTG MOLECULAR DIAGNOSTICS SECURES DEBT FACILITY WITH MIDCAP FINANCIAL

27 Mar 2018

BRIEF-HTG Molecular Q4 Loss Per Share $0.15

* HTG MOLECULAR DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

22 Mar 2018

BRIEF-Stonepine Capital Management Reports 5.6 Pct Passive Stake In HTG Molecular Diagnostics

* STONEPINE CAPITAL MANAGEMENT LLC REPORTS A 5.6 PERCENT PASSIVE STAKE IN HTG MOLECULAR DIAGNOSTICS INC AS OF JANUARY 19 - SEC FILING Source text - http://bit.ly/2G2Dlxg Further company coverage:

22 Jan 2018

Earnings vs. Estimates